Vetnostrum Business Summary

Vetnostrum (6936.TW) operates as a vertically integrated animal health leader in Taiwan, generating revenue through the manufacturing and distribution of veterinary pharmaceuticals and specialized feed additives. The company’s business is structured into four primary segments: therapeutic drugs, medicated feed additives, non-medicated feed additives, and a rapidly expanding portfolio of pet-use medications and supplements under the Koolpal brand. As the first veterinary drug manufacturer in Taiwan to achieve WHO GMP certification, Vetnostrum maintains a dominant domestic position, particularly in the livestock sector where its Amoxicillin products command over 50% market share. It competes directly with local players such as Synbio Tech and Lifeguard Pharmaceutical, as well as international giants like MSD Animal Health and Zoetis. While historically reliant on economic animals for over 95% of its top line, the company is currently executing a strategic pivot to increase its companion animal revenue share to 30% by 2030, leveraging its extensive portfolio of over 300 product licenses. The leadership team is anchored by Chairman and President Wei-Kai Chung, a third-generation executive from the prominent Yung Shin Pharmaceutical family with a management pedigree from the Asian Institute of Management. Under his direction, the company was formed through the 2016 acquisition of Zoetis’s Taiwan manufacturing assets and the subsequent integration of Yung Shin’s animal health division. Key executive support includes CFO Yi Fen Chen and Comptroller Wan Ting Tsai, who oversee a robust financial structure backed by parent company YungShin Global Holding (3705.TW), which retains a near-majority stake. The company enjoys significant institutional support from major Taiwanese investors, including Mega Financial, E.SUN Venture Capital, and China Steel’s investment arm (China Steel Management). The board of directors is further strengthened by independent experts such as Pao-Chu Lo and Pan-Chiang Yang, ensuring high standards of governance as Vetnostrum expands its footprint across the Asia-Pacific region.